Investing
AbbVie to buy ImmunoGen for $10.1 billion to boost cancer drug portfolio
© Reuters. FILE PHOTO: A sign stands outside a Abbvie facility in Cambridge, Massachusetts, U.S., May 20, 2021. REUTERS/Brian Snyder/File Photo
(Reuters) – AbbVie (NYSE:) said on Thursday it will buy drugmaker ImmunoGen (NASDAQ:) for $10.1 billion, boosting its presence in the market for cancer treatments.
The drugmaker will pay $31.26 per ImmunoGen share in cash, representing a premium of 94.6% to the last closing price.
This transaction is expected to close in the middle of 2024, AbbVie said.
Read the full article here
-
Side Hustles7 days ago
Microsoft Is About to Begin Job Cuts. Here’s Why.
-
Make Money6 days ago
10 Critical Questions to Ask Your Financial Advisor Now
-
Make Money5 days ago
10 Ways to Make Money As a Graphic Designer
-
Personal Finance4 days ago
If you are 60 years old, new 401(k) rules could save you money
-
Investing7 days ago
What CMOs Need to Know About AI Adoption in Marketing Teams
-
Investing5 days ago
Could Easier Cancellations Build Customer Loyalty?
-
Investing6 days ago
Airbus keeps top spot with 766 jet deliveries in 2024 By Reuters
-
Side Hustles7 days ago
JPMorgan to Implement a Five-Day Return-to-Office Mandate